Kura Oncology, Inc.
KURA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $20,750 | $15,288 | $14,108 | $53,883 |
| % Growth | 35.7% | 8.4% | -73.8% | – |
| Cost of Goods Sold | $3,212 | $0 | $0 | $0 |
| Gross Profit | $17,538 | $15,288 | $14,108 | $53,883 |
| % Margin | 84.5% | 100% | 100% | 100% |
| R&D Expenses | $67,908 | $62,785 | $55,973 | $52,267 |
| G&A Expenses | $32,839 | $25,169 | $22,835 | $24,071 |
| SG&A Expenses | $32,839 | $25,169 | $22,835 | $24,071 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$3,212 | $0 | $0 | $0 |
| Operating Expenses | $97,535 | $87,954 | $78,808 | $76,338 |
| Operating Income | -$79,997 | -$72,666 | -$64,700 | -$22,455 |
| % Margin | -385.5% | -475.3% | -458.6% | -41.7% |
| Other Income/Exp. Net | $5,881 | $6,544 | $7,497 | $5,256 |
| Pre-Tax Income | -$74,116 | -$66,122 | -$57,203 | -$17,199 |
| Tax Expense | $0 | $0 | $226 | $2,018 |
| Net Income | -$74,116 | -$66,122 | -$57,429 | -$19,217 |
| % Margin | -357.2% | -432.5% | -407.1% | -35.7% |
| EPS | -0.85 | -0.75 | -0.66 | -0.22 |
| % Growth | -13.3% | -13.6% | -200% | – |
| EPS Diluted | -0.85 | -0.75 | -0.66 | -0.22 |
| Weighted Avg Shares Out | 87,645 | 87,586 | 87,415 | 87,136 |
| Weighted Avg Shares Out Dil | 87,645 | 87,586 | 87,415 | 87,136 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,881 | $6,935 | $7,879 | $5,659 |
| Interest Expense | $0 | $391 | $382 | $403 |
| Depreciation & Amortization | $164 | $224 | -$7,115 | $204 |
| EBITDA | -$73,952 | -$65,507 | -$64,700 | -$16,592 |
| % Margin | -356.4% | -428.5% | -458.6% | -30.8% |